Vaccine Research
Vaccine Research
vacres
Medical Sciences
http://vacres.pasteur.ac.ir
1
admin
2383-2819
2423-4923
10.61186/vacres
en
jalali
1398
3
1
gregorian
2019
6
1
6
1
online
1
fulltext
en
Could Trivalent LAIV Protect Against Both Genetic Lineages of Influenza B Virus?
Vaccine development, efficacy and safety evaluation
Vaccine development, efficacy and safety evaluation
پژوهشي
Research
<strong>Introduction:</strong> The global co-circulation of two influenza B virus genetic lineages known as B/Yamagata and B/Victoria may lead to a mismatch between the circulating virus and the strain recommended for use in influenza vaccines. Little is known about the protective efficacy of unmatched influenza B strains, especially when it comes to live attenuated influenza vaccine. The main purpose of this study was to demonstrate the viability of using live attenuated influenza vaccine developed on B/USSR/60/69 backbone to protect from heterologous influenza B challenge infection.<br>
<strong>Methods:</strong> To estimate the potential cross-protective activity of mono- and trivalent live attenuated vaccines based on B/Victoria or B/Yamagata genetic lineage virus against a heterological challenge. Ferrets were given one dose of vaccine and then challenged with influenza B virus and monitored for clinical signs associated with influenza infection. Samples of the ferrets’ airways were tested for the presence of challenge virus.<br>
<strong>Results:</strong> Mono- and trivalent live attenuated influenza vaccines were shown to be safe and cross-protective against genetically different influenza B viruses based on virological and histological data and clinical signs. A lower titer of heterologous challenge virus in the airways of vaccinated ferrets compared to mock-vaccinated animals inoculated with challenge virus was detected. Interestingly, B/Victoria-based vaccines were more cross-protective compared with B/Yamagata-based vaccines.<br>
<strong>Conclusion:</strong> In the case of mismatches of B component of the trivalent live attenuated influenza vaccine and lineage of the circulating influenza B viruses, one of the options could be using trivalent preparation containing a B/Victoria lineage component.
,influenza,influenza B virus,live attenuated influenza vaccine,cross-protective activity
13
24
http://vacres.pasteur.ac.ir/browse.php?a_code=A-10-696-2&slc_lang=en&sid=1
Irina
Kiseleva
irina.v.kiseleva@mail.ru